<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143097">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02122484</url>
  </required_header>
  <id_info>
    <org_study_id>COL.CABG</org_study_id>
    <nct_id>NCT02122484</nct_id>
  </id_info>
  <brief_title>Colchicine in Coronary Artery Bypass Graft (CABG)</brief_title>
  <official_title>Study of Anti-inflammatory Treatment With Colchicine in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery to Reduce Reperfusion Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.Gennimatas General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Evangelismos Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G.Gennimatas General Hospital</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence that inflammatory processes may play a key role during surgical myocardial
      reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent,
      may lead to reduction in periprocedural infarct size, when administered during elective
      coronary artery bypass graft surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Myocardial damage marker levels</measure>
    <time_frame>Days 1-2 post-CABG</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>At one and at six months after CABG</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Elective Coronary Artery Bypass Graft Surgery</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients taking placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The study will enroll patients 18 years old or older who are eligible to undergo CABG
             surgery.

        Exclusion Criteria:

        Excluded are patients:

          -  with age &gt; 80 years old

          -  scheduled for concomitant valve surgery

          -  scheduled for coronary surgery without cardiopulmonary bypass

          -  with peripheral vascular disease aï¬€ecting the upper limbs

          -  with acute coronary syndrome within the previous 4 weeks

          -  on inotropic or mechanical circulatory support before induction of anaesthesia

          -  with any disorder that could potentially increase preoperative cTnI concentrations
             (eg, percutaneous coronary intervention within the previous 6 weeks)

          -  with active inflammatory diseases, infectious diseases or known malignancy

          -  under treatment with corticosteroids, anti-inflammatory agents or disease modifying
             agents

          -  with known hypersensitivity-allergy to colchicine

          -  under chronic treatment with colchicine

          -  with severe renal failure (eGFR &lt; 35 ml/min/1.73 m2)

          -  with hepatic failure (Child - Pugh class B or C)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spyridon Deftereos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Athens General Hospital &quot;G. Gennimatas&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Spyridon Deftereos, MD</last_name>
    <phone>+302107768560</phone>
    <email>spdeftereos@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Athens General Hospital &quot;G. Gennimatas&quot;</name>
      <address>
        <city>Athens</city>
        <state>Attika</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Spyridon Deftereos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Giannopoulos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos Angelidis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G.Gennimatas General Hospital</investigator_affiliation>
    <investigator_full_name>Spyridon Deftereos</investigator_full_name>
    <investigator_title>Director, Cardiac Catheterization Department</investigator_title>
  </responsible_party>
  <keyword>reperfusion damage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
